Janssen gets US FDA approval for Ponvory to treat multiple sclerosis
Ponvory is a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator that keeps lymphocytes out of the blood
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
22 Mar 21
Ponvory is a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator that keeps lymphocytes out of the blood
22 Mar 21
The new Covid-19 vaccine candidate is a virus like particle (VLP) triple antigen vaccine, which offers triple protection…
19 Mar 21
The new large-scale cell culture manufacturing facility in Holly Springs, North Carolina will create 725 jobs in the…
19 Mar 21
MHRA concluded that there is no evidence that blood clots in veins are occurring more than expected in…
18 Mar 21
Sana Biotechnology will use the iPSC cell lines from Fujifilm Cellular Dynamics to research, develop, manufacture, and commercialise…
17 Mar 21
AbbVie has acquired the portfolio of women's drugs as part of its $63bn acquisition of Allergan, completed last…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
16 Mar 21
Takeda will use the IDT’s capacity, previously reserved for its dengue vaccine candidate (TAK-003), to produce Janssen’s Covid-19…
15 Mar 21
Earlier, the Republic of Ireland took a similar decision over reports of blood clotting in adults in Norway
12 Mar 21
EC authorised the vaccine to prevent the Covid-19 in people aged 18 years and older, in all 27…
12 Mar 21
The MoH analysis showed at least 97% vaccine effectiveness against symptomatic Covid-19 cases, and 94% against asymptomatic SARS-CoV-2…